Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADimpact real-world study of lebrikizumab for burdensome body areas in moderate-to-severe atopic dermatitis
DRKS00041882Phase 4Recruiting
- Sponsor
- Almirall
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 4, open-label, single-arm trial of lebrikizumab in atopic dermatitis (AD), sponsored by Almirall. Primary endpoint: Dermatology-related quality of life. Started Sep 2026; status: recruiting.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on DRKS00041882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00041882.